Stemcentrx Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
147
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$6.43B
Stemcentrx General Information
Description
Provider of cancer research and drug-development services designed to find a new approach to treat cancer. The company's services provide therapies to eliminate cancer stem cells, which initiate and perpetuate tumors, enabling healthcare providers to cure cancer of their patients and improve their lives.
Contact Information
Website
www.stemcentrx.comCorporate Office
- 450 East Jamie Court
- South San Francisco, CA 94080
- United States
Corporate Office
- 450 East Jamie Court
- South San Francisco, CA 94080
- United States
Stemcentrx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 01-Jun-2016 | $6.43B | Completed | Clinical Trials - Phase 1 | ||
| 7. Later Stage VC (Series G) | 14-Aug-2015 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC (Series F) | 01-May-2014 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC | 01-Apr-2013 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series D) | 01-Feb-2012 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 16-Mar-2011 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | $3.25M | $9.2M | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | $6M | $6M | Completed | Generating Revenue |
Stemcentrx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series G | ||||||||
| Series F2 | ||||||||
| Series F1 | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A2 | 88,191,172 | $0.001000 | 8% | $0.07 | $0.07 | 1x | $0.07 | |
| Series A1 | 88,191,172 | $0.001000 | 8% | $0.07 | $0.07 | 1x | $0.07 | 40.47% |
Stemcentrx Comparisons
Industry
Financing
Details
Stemcentrx Competitors (46)
One of Stemcentrx’s 46 competitors is Pharmacyclics, a Venture Capital-Backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pharmacyclics | Venture Capital-Backed | San Francisco, CA | ||||
| Endeavor BioMedicines | Venture Capital-Backed | San Diego, CA | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Stemcentrx Signals
Stemcentrx Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AME Cloud Ventures | Venture Capital | Minority | ||
| ARTIS (San Francisco) | Venture Capital | Minority | ||
| American Funds Insurance Series | Government | Minority | ||
| Bennu Venture Group | Venture Capital | Minority | ||
| Columbia Pacific Advisors | Asset Manager | Minority |
Stemcentrx FAQs
-
When was Stemcentrx founded?
Stemcentrx was founded in 2008.
-
Where is Stemcentrx headquartered?
Stemcentrx is headquartered in South San Francisco, CA.
-
What is the size of Stemcentrx?
Stemcentrx has 147 total employees.
-
What industry is Stemcentrx in?
Stemcentrx’s primary industry is Drug Discovery.
-
Is Stemcentrx a private or public company?
Stemcentrx is a Private company.
-
What is the current valuation of Stemcentrx?
The current valuation of Stemcentrx is .
-
What is Stemcentrx’s current revenue?
The current revenue for Stemcentrx is .
-
How much funding has Stemcentrx raised over time?
Stemcentrx has raised $552M.
-
Who are Stemcentrx’s investors?
AME Cloud Ventures, ARTIS (San Francisco), American Funds Insurance Series, Bennu Venture Group, and Columbia Pacific Advisors are 5 of 16 investors who have invested in Stemcentrx.
-
Who are Stemcentrx’s competitors?
Pharmacyclics, Endeavor BioMedicines, Aro Biotherapeutics, NGM Biopharmaceuticals, and Inovio Pharmaceuticals are some of the 46 competitors of Stemcentrx.
-
When was Stemcentrx acquired?
Stemcentrx was acquired on 01-Jun-2016.
-
Who acquired Stemcentrx?
Stemcentrx was acquired by AbbVie.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process